Translationally, we identified Rabdosiin as a potential inhibitor of MKRN1 through virtual screening, and validated the synergetic effect of Rabdosiin and Oxa in treating Oxa-resistant CRC cells both in vitro and in vivo. Here, MKRN1 is linked to colorectal carcinoma.